SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories reports consolidated net profit of Rs 477.76 crore in Q2FY15

28 Oct 2014 Evaluate

Ranbaxy Laboratories has reported results for second quarter ended September 30, 2014.

The company has reported a net loss of Rs 368.26 crore for the quarter under review as compared to a net loss of Rs 842.23 crore for the same quarter in the previous year. Total income of the company has decreased 8.92% at Rs 1338.93 crore for Q2FY15 as compared Rs 1470.19 crore for the corresponding quarter previous year.

On consolidated basis, the company has posted a net profit after taxes and minority interest of Rs 477.76 crore for the quarter as against a net loss of Rs 454.17 crore in the September quarter of previous fiscal. The company’s total income has increased by 15.92% at Rs 3277.88 crore for the quarter from Rs 2827.73 crore in the similar quarter of previous year.

Peers
Company Name CMP
Sun Pharma Inds. 1652.75
Dr. Reddys Lab 1215.90
Cipla 1229.55
Zydus Lifesciences 927.75
Lupin 2309.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×